Immatics unveils promising, early-stage data for a top contender in the race to develop TCRs. Now it has to live up to expectations

Immatics has scored a significant advance in its quest to develop cell therapies for solid tumors.

Tuesday morning the biotech — based in Germany with a …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Im­mat­ics un­veils promis­ing, ear­ly-stage da­ta for a top con­tender in the race to de­vel­op TCRs. Now it has to live up to ex­pec­ta­tions